Review



dna pkcs targeting antibody  (Bethyl)


Bioz Verified Symbol Bethyl is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    Bethyl dna pkcs targeting antibody
    DNA-PKcs decreases the ability of STING agonists to trigger an antiviral response. (A) T98G cells were treated with the 10 µM diABZI, 1 µM E7766, or 10 mg/ml fluorinated 3′3′-cGAMP in combination or not with 2 µM of NU7441. Cells were subsequently infected or not with VSV-GFP for 16 h prior to DAPI nuclear staining and image acquisition. Images are representative of three independent experiments. (B) As in A, except that cells were infected with the MPXV clade 2b strain S2626 for 48 h. Images are representative of three independent experiments. (C) T98G cells engineered to express control <t>nontargeting</t> <t>or</t> <t>DNA-PKcs–targeting</t> gRNA were treated with 10 µg/ml fluorinated 3′3′-cGAMP in combination or not with 2 µM of NU7441. Cells were subsequently infected or not with VSV-GFP at MOI 0.3 for 16 h, prior to DAPI nuclear staining and image acquisition. Graph shows the mean (±SEM, n = 3 independent experiments) percentage of infected (GFP + ) cells as measured by fluorescent microscopy. Statistical significance was assessed using two-tailed Student's t test. (D) Gating strategy for macrophages used in . (E) Histograms show the percentage of infected (GFP + ) cells as measured by flow cytometry, following treatment with STING agonists, in the presence or absence of NU7441, at two different MOIs. (F) Primary macrophages from healthy donors 1, 2, and 3 were pretreated with NU7441 prior to STING agonist treatment. Cells treated with a STING agonist, and they were set as 100% infection, and the effect of adding a NU7441 was assessed relative to this condition. Scale bars, 500 μm. **: P < 0.01; *: P < 0.05. Data are from at least three independent experiments. Related to .
    Dna Pkcs Targeting Antibody, supplied by Bethyl, used in various techniques. Bioz Stars score: 93/100, based on 44 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dna+pkcs+targeting+antibody/DNA-PKcs+Antibody/pmc13011919-269-5-8
    Average 93 stars, based on 44 article reviews
    dna pkcs targeting antibody - by Bioz Stars, 2026-09
    93/100 stars

    Images

    1) Product Images from "DNA-PK interacts with cyclic dinucleotides and inhibits type I interferon responses"

    Article Title: DNA-PK interacts with cyclic dinucleotides and inhibits type I interferon responses

    Journal: The Journal of Experimental Medicine

    doi: 10.1084/jem.20251796

    DNA-PKcs decreases the ability of STING agonists to trigger an antiviral response. (A) T98G cells were treated with the 10 µM diABZI, 1 µM E7766, or 10 mg/ml fluorinated 3′3′-cGAMP in combination or not with 2 µM of NU7441. Cells were subsequently infected or not with VSV-GFP for 16 h prior to DAPI nuclear staining and image acquisition. Images are representative of three independent experiments. (B) As in A, except that cells were infected with the MPXV clade 2b strain S2626 for 48 h. Images are representative of three independent experiments. (C) T98G cells engineered to express control nontargeting or DNA-PKcs–targeting gRNA were treated with 10 µg/ml fluorinated 3′3′-cGAMP in combination or not with 2 µM of NU7441. Cells were subsequently infected or not with VSV-GFP at MOI 0.3 for 16 h, prior to DAPI nuclear staining and image acquisition. Graph shows the mean (±SEM, n = 3 independent experiments) percentage of infected (GFP + ) cells as measured by fluorescent microscopy. Statistical significance was assessed using two-tailed Student's t test. (D) Gating strategy for macrophages used in . (E) Histograms show the percentage of infected (GFP + ) cells as measured by flow cytometry, following treatment with STING agonists, in the presence or absence of NU7441, at two different MOIs. (F) Primary macrophages from healthy donors 1, 2, and 3 were pretreated with NU7441 prior to STING agonist treatment. Cells treated with a STING agonist, and they were set as 100% infection, and the effect of adding a NU7441 was assessed relative to this condition. Scale bars, 500 μm. **: P < 0.01; *: P < 0.05. Data are from at least three independent experiments. Related to .
    Figure Legend Snippet: DNA-PKcs decreases the ability of STING agonists to trigger an antiviral response. (A) T98G cells were treated with the 10 µM diABZI, 1 µM E7766, or 10 mg/ml fluorinated 3′3′-cGAMP in combination or not with 2 µM of NU7441. Cells were subsequently infected or not with VSV-GFP for 16 h prior to DAPI nuclear staining and image acquisition. Images are representative of three independent experiments. (B) As in A, except that cells were infected with the MPXV clade 2b strain S2626 for 48 h. Images are representative of three independent experiments. (C) T98G cells engineered to express control nontargeting or DNA-PKcs–targeting gRNA were treated with 10 µg/ml fluorinated 3′3′-cGAMP in combination or not with 2 µM of NU7441. Cells were subsequently infected or not with VSV-GFP at MOI 0.3 for 16 h, prior to DAPI nuclear staining and image acquisition. Graph shows the mean (±SEM, n = 3 independent experiments) percentage of infected (GFP + ) cells as measured by fluorescent microscopy. Statistical significance was assessed using two-tailed Student's t test. (D) Gating strategy for macrophages used in . (E) Histograms show the percentage of infected (GFP + ) cells as measured by flow cytometry, following treatment with STING agonists, in the presence or absence of NU7441, at two different MOIs. (F) Primary macrophages from healthy donors 1, 2, and 3 were pretreated with NU7441 prior to STING agonist treatment. Cells treated with a STING agonist, and they were set as 100% infection, and the effect of adding a NU7441 was assessed relative to this condition. Scale bars, 500 μm. **: P < 0.01; *: P < 0.05. Data are from at least three independent experiments. Related to .

    Techniques Used: Infection, Staining, Control, Microscopy, Two Tailed Test, Flow Cytometry

    Related Articles

    Immunoprecipitation:

    Article Title: DNA-PK controls cyclic dinucleotide-associated type I Interferon responses
    Article Snippet: .. Endogenous immunoprecipitation was performed using DNA-PKcs-targeting antibody (A300-517A, Bethyl), or Rabbit IgG (Santa Cruz) as a negative control. .. After an overnight incubation at 4°C on a wheel, immunoprecipitation was performed using Protein G Sepharose Fast Flow beads (Sigma).

    Article Title: DNA-PK interacts with cyclic dinucleotides and inhibits type I interferon responses.
    Article Snippet: .. Endogenous immunoprecipitation was performed using DNA-PKcs– targeting antibody (A300-517A; Bethyl) or Rabbit IgG (Santa Cruz) as a negative control. .. After an overnight incubation at 4°C on a wheel, immunoprecipitation was performed using Protein G Sepharose Fast Flow beads (Sigma-Aldrich).

    Article Title: DNA-PK interacts with cyclic dinucleotides and inhibits type I interferon responses
    Article Snippet: .. Endogenous immunoprecipitation was performed using DNA-PKcs–targeting antibody (A300-517A; Bethyl) or Rabbit IgG (Santa Cruz) as a negative control. .. After an overnight incubation at 4°C on a wheel, immunoprecipitation was performed using Protein G Sepharose Fast Flow beads (Sigma-Aldrich).

    Negative Control:

    Article Title: DNA-PK controls cyclic dinucleotide-associated type I Interferon responses
    Article Snippet: .. Endogenous immunoprecipitation was performed using DNA-PKcs-targeting antibody (A300-517A, Bethyl), or Rabbit IgG (Santa Cruz) as a negative control. .. After an overnight incubation at 4°C on a wheel, immunoprecipitation was performed using Protein G Sepharose Fast Flow beads (Sigma).

    Article Title: DNA-PK interacts with cyclic dinucleotides and inhibits type I interferon responses.
    Article Snippet: .. Endogenous immunoprecipitation was performed using DNA-PKcs– targeting antibody (A300-517A; Bethyl) or Rabbit IgG (Santa Cruz) as a negative control. .. After an overnight incubation at 4°C on a wheel, immunoprecipitation was performed using Protein G Sepharose Fast Flow beads (Sigma-Aldrich).

    Article Title: DNA-PK interacts with cyclic dinucleotides and inhibits type I interferon responses
    Article Snippet: .. Endogenous immunoprecipitation was performed using DNA-PKcs–targeting antibody (A300-517A; Bethyl) or Rabbit IgG (Santa Cruz) as a negative control. .. After an overnight incubation at 4°C on a wheel, immunoprecipitation was performed using Protein G Sepharose Fast Flow beads (Sigma-Aldrich).



    Similar Products

    dna pkcs targeting antibody  (Bethyl)
    93
    Bethyl dna pkcs targeting antibody
    DNA-PKcs decreases the ability of STING agonists to trigger an antiviral response. (A) T98G cells were treated with the 10 µM diABZI, 1 µM E7766, or 10 mg/ml fluorinated 3′3′-cGAMP in combination or not with 2 µM of NU7441. Cells were subsequently infected or not with VSV-GFP for 16 h prior to DAPI nuclear staining and image acquisition. Images are representative of three independent experiments. (B) As in A, except that cells were infected with the MPXV clade 2b strain S2626 for 48 h. Images are representative of three independent experiments. (C) T98G cells engineered to express control <t>nontargeting</t> <t>or</t> <t>DNA-PKcs–targeting</t> gRNA were treated with 10 µg/ml fluorinated 3′3′-cGAMP in combination or not with 2 µM of NU7441. Cells were subsequently infected or not with VSV-GFP at MOI 0.3 for 16 h, prior to DAPI nuclear staining and image acquisition. Graph shows the mean (±SEM, n = 3 independent experiments) percentage of infected (GFP + ) cells as measured by fluorescent microscopy. Statistical significance was assessed using two-tailed Student's t test. (D) Gating strategy for macrophages used in . (E) Histograms show the percentage of infected (GFP + ) cells as measured by flow cytometry, following treatment with STING agonists, in the presence or absence of NU7441, at two different MOIs. (F) Primary macrophages from healthy donors 1, 2, and 3 were pretreated with NU7441 prior to STING agonist treatment. Cells treated with a STING agonist, and they were set as 100% infection, and the effect of adding a NU7441 was assessed relative to this condition. Scale bars, 500 μm. **: P < 0.01; *: P < 0.05. Data are from at least three independent experiments. Related to .
    Dna Pkcs Targeting Antibody, supplied by Bethyl, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dna+pkcs+targeting+antibody/DNA-PKcs+Antibody/pmc13011919-269-5-8
    Average 93 stars, based on 1 article reviews
    dna pkcs targeting antibody - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier
    antibodies targeting phospho-dna–protein kinase catalytic subunit (pkcs)  (Cell Signaling Technology Inc)
    90
    Cell Signaling Technology Inc antibodies targeting phospho-dna–protein kinase catalytic subunit (pkcs)
    DNA-PKcs decreases the ability of STING agonists to trigger an antiviral response. (A) T98G cells were treated with the 10 µM diABZI, 1 µM E7766, or 10 mg/ml fluorinated 3′3′-cGAMP in combination or not with 2 µM of NU7441. Cells were subsequently infected or not with VSV-GFP for 16 h prior to DAPI nuclear staining and image acquisition. Images are representative of three independent experiments. (B) As in A, except that cells were infected with the MPXV clade 2b strain S2626 for 48 h. Images are representative of three independent experiments. (C) T98G cells engineered to express control <t>nontargeting</t> <t>or</t> <t>DNA-PKcs–targeting</t> gRNA were treated with 10 µg/ml fluorinated 3′3′-cGAMP in combination or not with 2 µM of NU7441. Cells were subsequently infected or not with VSV-GFP at MOI 0.3 for 16 h, prior to DAPI nuclear staining and image acquisition. Graph shows the mean (±SEM, n = 3 independent experiments) percentage of infected (GFP + ) cells as measured by fluorescent microscopy. Statistical significance was assessed using two-tailed Student's t test. (D) Gating strategy for macrophages used in . (E) Histograms show the percentage of infected (GFP + ) cells as measured by flow cytometry, following treatment with STING agonists, in the presence or absence of NU7441, at two different MOIs. (F) Primary macrophages from healthy donors 1, 2, and 3 were pretreated with NU7441 prior to STING agonist treatment. Cells treated with a STING agonist, and they were set as 100% infection, and the effect of adding a NU7441 was assessed relative to this condition. Scale bars, 500 μm. **: P < 0.01; *: P < 0.05. Data are from at least three independent experiments. Related to .
    Antibodies Targeting Phospho Dna–Protein Kinase Catalytic Subunit (Pkcs), supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dna+pkcs+targeting+antibody/antibodies+targeting+phospho+dna+protein+kinase+catalytic+subunit++pkcs+/pm37438719-86-34-55
    Average 90 stars, based on 1 article reviews
    antibodies targeting phospho-dna–protein kinase catalytic subunit (pkcs) - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    DNA-PKcs decreases the ability of STING agonists to trigger an antiviral response. (A) T98G cells were treated with the 10 µM diABZI, 1 µM E7766, or 10 mg/ml fluorinated 3′3′-cGAMP in combination or not with 2 µM of NU7441. Cells were subsequently infected or not with VSV-GFP for 16 h prior to DAPI nuclear staining and image acquisition. Images are representative of three independent experiments. (B) As in A, except that cells were infected with the MPXV clade 2b strain S2626 for 48 h. Images are representative of three independent experiments. (C) T98G cells engineered to express control nontargeting or DNA-PKcs–targeting gRNA were treated with 10 µg/ml fluorinated 3′3′-cGAMP in combination or not with 2 µM of NU7441. Cells were subsequently infected or not with VSV-GFP at MOI 0.3 for 16 h, prior to DAPI nuclear staining and image acquisition. Graph shows the mean (±SEM, n = 3 independent experiments) percentage of infected (GFP + ) cells as measured by fluorescent microscopy. Statistical significance was assessed using two-tailed Student's t test. (D) Gating strategy for macrophages used in . (E) Histograms show the percentage of infected (GFP + ) cells as measured by flow cytometry, following treatment with STING agonists, in the presence or absence of NU7441, at two different MOIs. (F) Primary macrophages from healthy donors 1, 2, and 3 were pretreated with NU7441 prior to STING agonist treatment. Cells treated with a STING agonist, and they were set as 100% infection, and the effect of adding a NU7441 was assessed relative to this condition. Scale bars, 500 μm. **: P < 0.01; *: P < 0.05. Data are from at least three independent experiments. Related to .

    Journal: The Journal of Experimental Medicine

    Article Title: DNA-PK interacts with cyclic dinucleotides and inhibits type I interferon responses

    doi: 10.1084/jem.20251796

    Figure Lengend Snippet: DNA-PKcs decreases the ability of STING agonists to trigger an antiviral response. (A) T98G cells were treated with the 10 µM diABZI, 1 µM E7766, or 10 mg/ml fluorinated 3′3′-cGAMP in combination or not with 2 µM of NU7441. Cells were subsequently infected or not with VSV-GFP for 16 h prior to DAPI nuclear staining and image acquisition. Images are representative of three independent experiments. (B) As in A, except that cells were infected with the MPXV clade 2b strain S2626 for 48 h. Images are representative of three independent experiments. (C) T98G cells engineered to express control nontargeting or DNA-PKcs–targeting gRNA were treated with 10 µg/ml fluorinated 3′3′-cGAMP in combination or not with 2 µM of NU7441. Cells were subsequently infected or not with VSV-GFP at MOI 0.3 for 16 h, prior to DAPI nuclear staining and image acquisition. Graph shows the mean (±SEM, n = 3 independent experiments) percentage of infected (GFP + ) cells as measured by fluorescent microscopy. Statistical significance was assessed using two-tailed Student's t test. (D) Gating strategy for macrophages used in . (E) Histograms show the percentage of infected (GFP + ) cells as measured by flow cytometry, following treatment with STING agonists, in the presence or absence of NU7441, at two different MOIs. (F) Primary macrophages from healthy donors 1, 2, and 3 were pretreated with NU7441 prior to STING agonist treatment. Cells treated with a STING agonist, and they were set as 100% infection, and the effect of adding a NU7441 was assessed relative to this condition. Scale bars, 500 μm. **: P < 0.01; *: P < 0.05. Data are from at least three independent experiments. Related to .

    Article Snippet: Endogenous immunoprecipitation was performed using DNA-PKcs–targeting antibody (A300-517A; Bethyl) or Rabbit IgG (Santa Cruz) as a negative control.

    Techniques: Infection, Staining, Control, Microscopy, Two Tailed Test, Flow Cytometry